IDEAYA Biosciences, Inc. (IDYA)

Market Cap	2.77B
Revenue (ttm)	23.39M
Net Income (ttm)	-112.96M
Shares Out	74.56M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	4.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	704,849
Open	37.38
Previous Close	37.62
Day's Range	36.58 - 38.30
52-Week Range	14.46 - 47.74
Beta	0.80
Analysts	Strong Buy
Price Target	45.70 (+23.08%)
Earnings Date	May 7, 2024

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: IDYA

Financial Performance

In 2023, IDYA's revenue was $23.39 million, a decrease of -54.08% compared to the previous year's $50.93 million. Losses were -$112.96 million, 92.6% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is $45.7, which is an increase of 23.08% from the latest price.

Price Target

$45.7

(23.08% upside)

Analyst Consensus: Strong Buy